Basecamp Research has raised a $140 million Series C to develop AI-designed medicines for patients with cancer, autoimmune disorders and other diseases. The London company trains biological foundation models on genomic data gathered through global partnerships, then uses the models to design components for experimental treatments. S32 led the round, Tech.eu reported.
The starting point is Basecamp’s proprietary genomic dataset, which it says comes from partnerships in more than 30 countries. Its Eden models use that material to design long, complex DNA sequences. Basecamp then pairs those sequences with specialized enzymes intended to deliver them precisely inside the body. The intended result is an AI-designed therapeutic candidate, not merely a biological prediction.
Basecamp’s first focus is in vivo cell therapy: reprogramming a patient’s cells inside the body. The company says current cell therapies are constrained by the complexity of what they can deliver and by burdensome patient-level manufacturing. Its proposed route is meant to carry more complex, customizable genetic instructions and make treatment simpler to administer.
The financing brings prominent AI and public-sector investors into that effort. Nvidia’s NVentures returned, while Anthropic’s Anthology Fund, a partnership with Menlo Ventures, joined as a new investor. The United Kingdom’s Sovereign AI Fund and the NATO Innovation Fund also participated.
Basecamp said the money will train a new generation of its AI models and advance its therapeutic pipeline. The company reported strong preclinical results across multiple disease areas, but those findings have not yet been tested in clinical development. For now, its pipeline remains preclinical and is moving toward human studies.